gms | German Medical Science

76. Jahresversammlung der Deutschen Gesellschaft für Hals-Nasen-Ohren-Heilkunde, Kopf- und Hals-Chirurgie e. V.

Deutsche Gesellschaft für Hals-Nasen-Ohren-Heilkunde, Kopf- und Hals-Chirurgie e. V.

04.05. - 08.05.2005, Erfurt

Do routine blood values correlate with the recurrence or the 10 year survival rate of head and neck cancer?

Meeting Abstract

  • corresponding author Miriam Steuer-Vogt - Clinic of the Technical University of Munich, Munich
  • author Claudius Fauser - Clinic of the Technical University of Munich, Munich
  • Viktor Bonkowsky - Clinic of Nürnberg, Nürnberg
  • Petra Ambrosch - University Clinic, Schleswig-Holstein, Campus Kiel, Kiel
  • Michael Scholz - Clinic of the Technical University of Munich, Munich
  • Katharina Licht - University Clinic of Regensburg, Regensburg

Deutsche Gesellschaft für Hals-Nasen-Ohren-Heilkunde, Kopf- und Hals-Chirurgie. 76. Jahresversammlung der Deutschen Gesellschaft für Hals-Nasen-Ohren-Heilkunde, Kopf- und Hals-Chirurgie e.V.. Erfurt, 04.-08.05.2005. Düsseldorf, Köln: German Medical Science; 2005. Doc05hno635

Die elektronische Version dieses Artikels ist vollständig und ist verfügbar unter: http://www.egms.de/de/meetings/hno2005/05hno171.shtml

Veröffentlicht: 22. September 2005

© 2005 Steuer-Vogt et al.
Dieser Artikel ist ein Open Access-Artikel und steht unter den Creative Commons Lizenzbedingungen (http://creativecommons.org/licenses/by-nc-nd/3.0/deed.de). Er darf vervielf&aauml;ltigt, verbreitet und &oauml;ffentlich zug&aauml;nglich gemacht werden, vorausgesetzt dass Autor und Quelle genannt werden.


Gliederung

Text

The following data was derived from a prospective, randomised, multi-centre trial of patients with head and neck cancer. This trial evaluated an adjuvant mistletoe treatment and demonstrated no beneficial effects in head and neck cancer patients (Eur J Cancer 2001; 37:23-31). The current question is: do values of routine blood examinations or acute phase proteins correlate with the recurrence or the 10 year survival rate of head and neck carcinoma?

Method: Here, 362 patients were randomly selected and blood samples were taken at up to 12 different time points (before treatment and after 8,12,16,22,28,32,44,48,60,72, or 84 weeks of treatment). The examined parameters were: γ-GT, GOT, GPT, haemoglobin, haptoglobin, CRP, α1-glykoprotein, fibrinogen und differentiated blood count.

Before treatment these patients had the following stage grouping and primary localization: I : (n=76), II (n=77), III (n=74), IV (n=135). Oral cavity (n=58), oropharynx (n=99), hypopharynx (n=60), larynx (n=136) [lips (n=6)]. The median follow up time was 80 months.

Results: The average and standard deviation were calculated for the different time points. Before treatment there was a correlation between the stage grouping and GPT, haemoglobin, CRP, α1-glykoprotein und fibrinogen. There was no difference in any parameter for the different tumour localizations. When compared to the baseline, none of the parameters correlated with the relative risk of disease free survival or the over all survival. Furthermore, there was no correlation of any parameter over the follow up period.

Thus, none of the above routine blood sample values can serve as a predicting factor in head and neck cancer patients.

Kindly supported by BMBS; Wilhelm Sander-Foundation; Matthias Lackas-Foundation